Steglujan (Ertugliflozin/Sitagliptin Phos) Patent Expiration, LOE Window & CMS Spending
Steglujan (Ertugliflozin/Sitagliptin Phos) by Merck & Co.: FDA Orange Book core substance LOE 2031-12-19, 0 AB generics, $1.9M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N209805 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-12-19 |
| Last Listed Patent or Exclusivity Date | 2031-12-19 |
| Orange Book Patents (*PED Extensions) | 5 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.9M |
| 2024 Medicare Part D Spend | $978K |
| 2024 Medicaid Spend | $958K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.